title: [Is the combination of remifentanil and propopfol suitable for transsphenoid resection of the hypophysis?].
abstract: In a multi-center trial, the feasibility of combining remifentanil (RF) and target-controlled infusion of propofol (P) for patients undergoing transsphenoidal resection of the pituitary gland was tested. After IRB approval, 74 patients (29 male/45 female) were included in the study. The concentration of RF and the target concentration of P were recorded as were heart rate (HR) and mean arterial blood pressure (MAP). For intubation the RF dosage was 0.26 +/- 0.06 microgram.kg-1.min-1 and the target concentration of P was 3.16 +/- 0.63 micrograms.ml-1. After induction, HR and MAP decreased significantly. The painful events of the operation were preparation of the nasal mucous membrane and penetration of the sella turcica. By adjusting the RF dose to 0.31 +/- 0.09 microgram.kg-1. min-1 and the target concentration of P to 3.48 +/- 1.49 micrograms.ml-1, an increase of HR and MAP above initial values was avoided at this time. Hypotension and bardycardia were treated in eight patients (10.8%) with a vasopressor, in four patients (5.4%) with atropine and in four more patients (5.4%) with a combination of these drugs. Two patients (2.7%) needed antihypertensive therapy. The average time interval between the end of P-TCI and spontaneous breathing was 6 +/- 3 min (median 6 min) and till patients opened their eyes 9 +/- 4 min (median 9 min). After 13 +/- 4 min (median 13 min) the patients became orientated. The average doses of analgetics were 19.5 +/- 19.9 mg piritramide and 1.8 +/- 1.0 g metamizol during the first 12 hours postoperatively. Eight patients (10.8%) did not need any analgetics. We suggest that the combination of RF and P as a "fast track concept" can supplement the repertoire of anaesthetic managements used for transsphenoidal resection of the pituitary gland.
authors.affiliation: Klinik und Poliklinik für Anästhesiologie und Intensivtherapie am Universitätsklinikum Leipzig. schal@medizin.uni-leipzig.de
authors.forename: L
authors.initials: L
authors.lastname: Schaffranietz
authors.forename: H
authors.initials: H
authors.lastname: Wölfel
authors.forename: H
authors.initials: H
authors.lastname: Fritz
authors.forename: C
authors.initials: C
authors.lastname: Rudolph
mesh_terms: D000236:Adenoma / Q000601:surgery*; D000328:Adult; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General / Q000009:adverse effects; D018686:Anesthetics, Intravenous / Q000009:adverse effects / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects; D005240:Feasibility Studies; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007016:Hypophysectomy; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics; D010911:Pituitary Neoplasms / Q000601:surgery*; D015742:Propofol / Q000009:adverse effects / Q000493:pharmacokinetics; D000077208:Remifentanil; D013101:Sphenoid Sinus
chemical_list: D018686:Anesthetics, Intravenous; D010880:Piperidines; D000077208:Remifentanil; D015742:Propofol